Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Ductal Carcinoma In Situ: early-phase trial registry
10 of 16 indexed Breast Ductal Carcinoma In Situ trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 10 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Breast Ductal Carcinoma In Situ: 16 US clinical trials tracked, 10 recruiting.
Breast Ductal Carcinoma In Situ is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition breast-ductal-carcinoma-in-situ
OPEN 10 | RECR 63% | LATE 1 | EARLY 9 | RANK #1060 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Advanced Gastroesophageal Junction Adenocarcinoma (63% recruiting · 8 trials)
Breast Ductal Carcinoma In Situ lists 10 open slots (63% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Ductal Carcinoma In Situ on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Ductal Carcinoma In Situ is recruiting above its size-band peers.
10 of 16 indexed trials (62.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Breast Ductal Carcinoma In Situ research.
National Cancer Institute (NCI) accounts for 5 of 16 trials (31.3%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Ductal Carcinoma In Situ enrolment sits around 113 participants.
Median target enrolment is 113 among the 16 trials that report a genuine target (sentinel values excluded). 8 of those (50%) plan for fewer than 100 participants.
-
Breast Ductal Carcinoma In Situ research is mostly interventional.
15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Identifying and Caring for Individuals With Inherited Cancer Syndrome
OHSU Knight Cancer Institute
NCT04494945
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
M.D. Anderson Cancer Center
NCT04169542
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
National Cancer Institute (NCI)
NCT06184750
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
Roswell Park Cancer Institute
NCT06350500
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
National Cancer Institute (NCI)
NCT05941520
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Thomas Jefferson University
NCT04959474
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
National Cancer Institute (NCI)
NCT06195306
Neoadjuvant Breast Cancer Time Restricted Eating
Thomas Jefferson University
NCT05327608
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
NCT04144023
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
NCT06538389
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
NCT01272037
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
City of Hope Medical Center
NCT05340673
Metformin and Nightly Fasting in Women With Early Breast Cancer
M.D. Anderson Cancer Center
NCT05023967
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
Northwestern University
NCT05545150
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
National Cancer Institute (NCI)
NCT03317405
EMBr Wave for the Reduction of Hot Flashes in Women With a History of Breast Cancer
Ohio State University Comprehensive Cancer Center
NCT05086705
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Ductal Carcinoma In Situ records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Ductal Carcinoma In Situ trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Ductal Carcinoma In Situ page
16 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Breast Ductal Carcinoma In Situ trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Breast Ductal Carcinoma In Situ trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Ductal Carcinoma In Situ condition card totals 16 registered trials; most-linked intervention Questionnaire Administration; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.